This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride
Name: Anagrelide hydrochloride
Description: A platelet count of ≤600x10^9/L after 12 months is considered at least a partial response.
Measure: Number of Patients With Platelet Count ≤600x10^9/L After 12 Months Time: 1 yearDescription: A platelet count of ≤400x10^9/L after 12 months is considered a complete response.
Measure: Number of Patients With Platelet Count ≤400x10^9/L After 12 Months Time: 1 yearCase-Only
There is one SNP
An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride). --- V617F ---
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride Number of Patients With Platelet Count ≤600x10^9/L After 12 Months. --- V617F ---